Clinical Trials Browser

Phase 1 × palbociclib × Breast × Clear all

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT04288089 2026-02-27

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Phase 1 Active not recruiting

31 enrolled 12 charts

Breast Neoplasms

NCT03332797 2026-02-13

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT02499146 2026-02-11

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Phase 1 Completed

26 enrolled 40 charts

Advanced Breast Cancer

NCT05238922 2026-02-10

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT04360941 2026-01-21

PAveMenT

Phase 1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03685331 2026-01-09

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT05266105 2025-11-24

A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

Phase 1 Active not recruiting

Breast Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Phase 1 Active not recruiting

Breast Neoplasms

NCT06570031 2025-07-02

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT06941142 2025-04-23

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Phase 1 Not yet recruiting

Advanced Breast Cancer

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT03854903 2025-02-06

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT04818632 2024-12-17

AZD9833

Phase 1 Completed

Breast Neoplasms

NCT05293964 2024-11-29

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT03238196 2024-11-14

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Phase 1 Completed

35 enrolled 19 charts

Breast Neoplasms

NCT04060862 2024-11-08

IPATunity150

Phase 1 Terminated

20 enrolled 11 charts

Breast Neoplasms

NCT03900884 2024-11-07

PALVEN

Phase 1 Active not recruiting

Breast Neoplasm Female

NCT02389842 2024-09-26

PIPA

Phase 1 Completed

Breast Neoplasms

NCT02599714 2024-06-06

PASTOR

Phase 1 Completed

Breast Neoplasms

NCT06307249 2024-03-12

PTST_PALBEVA

Phase 1 Recruiting

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Inflammation, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02897375 2023-10-10

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Phase 1 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT06065592 2023-10-06

CAT_PB

Phase 1 Unknown

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Cardiovascular Diseases, Colonic Neoplasms, Carcinoma, Hepatocellular, Immune System Diseases, Inflammation, Lung Neoplasms, Neoplasms, Prostatic Neoplasms, Thromboembolism, Thrombosis

NCT04872608 2023-04-28

A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT03455270 2022-12-15

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Phase 1 Completed

Breast Neoplasms, Carcinoma, Ductal, Breast

NCT03128619 2022-09-26

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT02684032 2022-07-27

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT02626507 2022-02-09

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

Phase 1 Unknown

Breast Neoplasms

NCT01976169 2022-02-08

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

Phase 1 Completed

Breast Neoplasms

NCT04585724 2021-10-18

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Phase 1 Withdrawn

Brain Neoplasms, Breast Neoplasms

NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Phase 1 Withdrawn

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

NCT04856371 2021-04-23

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Phase 1 Unknown

Advanced Breast Cancer

NCT01320592 2020-04-08

PD0332991/Paclitaxel in Advanced Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT01602887 2012-11-12

Relative Bioavailability Study

Phase 1 Completed

Breast Neoplasms